DAVID GARCÍA HERRANZ-rekin lankidetzan egindako argitalpenak (12)

2024

  1. Influence of sex on chronic steroid-induced glaucoma: 24-Weeks follow-up study in rats

    Experimental Eye Research, Vol. 238

2023

  1. Microesferas biodegradables cargadas con dexametasona para el desarrollo de modelos animales de glaucoma crónico: la influencia de la adición de fibronectina por doble emulsión

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

2022

  1. Mimicking chronic glaucoma over 6 months with a single intracameral injection of dexamethasone/fibronectin-loaded PLGA microspheres

    Drug Delivery, Vol. 29, Núm. 1, pp. 2357-2374

  2. Tunable degrees of neurodegeneration in rats based on microsphere-induced models of chronic glaucoma

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Analysis of parainflammation in chronic glaucoma using vitreous-oct imaging

    Biomedicines, Vol. 9, Núm. 12

  2. Chronic glaucoma using biodegradable microspheres to induce intraocular pressure elevation. Six-month follow-up

    Biomedicines, Vol. 9, Núm. 6

  3. Influence of chronic ocular hypertension on emmetropia: Refractive, structural and functional study in two rat models

    Journal of Clinical Medicine, Vol. 10, Núm. 16

  4. Influence of sex on neuroretinal degeneration: Six-month follow-up in rats with chronic glaucoma

    Investigative Ophthalmology and Visual Science, Vol. 62, Núm. 13

  5. Long-term corticosteroid-induced chronic glaucoma model produced by intracameral injection of dexamethasone-loaded PLGA microspheres

    Drug Delivery, Vol. 28, Núm. 1, pp. 2427-2446

  6. Modelo animal de glaucoma crónico inducido con microesferas biodegradables: influencia de la adición de dexametasona

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 60-62

  7. Novel use of plga microspheres to create an animal model of glaucoma with progressive neuroretinal degeneration

    Pharmaceutics, Vol. 13, Núm. 2, pp. 1-20

2019

  1. Combination therapy and co-delivery strategies to optimize treatment of posterior segment neurodegenerative diseases

    Drug Discovery Today, Vol. 24, Núm. 8, pp. 1644-1653